

Burns portfolio

Prepare the burn site
Protect from infection
Progress to healing




The problem

- Burns are a global public health problem, accounting for an estimated 180 000 deaths annually. The majority of these occur in low- and middle-income countries¹
- When burns are non fatal they are a leading cause of morbidity, including prolonged hospitalization, disfigurement and disability, often with resulting stigma and rejection¹

The Smith+Nephew Burns portfolio is designed to help mitigate the complications associated with burn injuries.




Prepare – the wound bed




Early excision, the gold-standard treatment, attenuates the hypermetabolic state and removes the biological nidus for infection, thereby reducing the risk of burn wound sepsis.¹

Protect – from infection



Topical antimicrobials slow the septic process and have been instrumental in preventing those with larger, more-severe burns from succumbing to sepsis.¹

Progress – to healing




Temporary skin substitutes support re-epithelialisation.¹

Prepare

VERSAJET[®] II Hydrosurgery System **Accelerate your surgical debridement***¹⁻³

The VERSAJET II System is a powered surgical tool that is specially designed to improve care for patients undergoing wound debridement.

- Provides a smoother, more regular and consistent wound bed (ready to receive skin graft)*⁴
- The VERSAJET System has shown to be effective at removing biofilm from contaminated tissues. (If bacteria remain in the wound they can rapidly re-form biofilm and/or cause localised infection. The VERSAJET System's mode of action means biofilms are disrupted and evacuated)^{†5}
- Provides controlled debridement and facilitates precise excision of necrosis and other unwanted material from the wound surface, thus preserving viable tissue.^{6,7}
- Shown to precisely and safely debride (superficial and intermediate depth) burned necrotic tissue^{‡8}



Protect



ACTICOAT Antimicrobial Barrier Dressing*

Fast and effective

ACTICOAT Dressing contains nanocrystalline silver technology - clinically proven in both paediatrics and adults to help reduce/minimise risk of infection.¹⁻⁴

- Fast acting, kills bacteria in as little as 30 minutes^{†5-10}
- Effective against a broad spectrum of gram positive and gram negative bacterial and fungal wound pathogens^{†5,6,11-15}
- Conforms to anatomical areas and minimises risk of trauma to the wound at dressing removal^{16,17}



INTRASITE Gel and **INTRASITE** Conformable Hydrogel Wound Dressings

INTRASITE Dressing is an amorphous hydrogel which promotes autolytic debridement by re-hydrating necrotic tissue.¹⁻⁵

- INTRASITE Dressing absorbs excess exudate[‡] and slough^{1,2,5}
- Can be used in conjunction with ACTICOAT Antimicrobial Barrier Dressing⁶⁻⁹
- INTRASITE Dressing helps promote granulation tissue¹⁰⁻¹²

Progress



BIOBRANE Temporary Biosynthetic Skin Dressing

BIOBRANE Dressing is a temporary biosynthetic wound dressing that can be used on extensive body surface area wounds whilst being easy to apply.¹⁻⁵


- Conformable to surfaces allowing joint movement^{4,6}
- Increased speed of healing and epithelialisation compared to silver sulfadiazine⁷⁻¹⁰
- May be used in paediatric patients,^{4,11,12} and requires a limited number of dressing changes compared to standard of care^{13,14}



RENASYS Negative Pressure Wound Therapy System

RENASYS is a Negative Pressure Wound Therapy (tNPWT) system with both foam and gauze interfaces to help prepare the wound bed for healing or grafting.

- NPWT may help reduce oedema in partial thickness burns¹⁻³
- Helps promote granulation tissue formation⁴⁻⁶
- Removes exudate and promotes moisture balance within the wound bed^{4,7-10}



PICO Single Use Negative Wound Therapy System (sNPWT)

The PICO System gives you all the benefits of NPWT, but simplified, and provides up to 7 or 14 days of NPWT.

- The PICO System facilitates successful graft take¹⁻⁴
- The PICO Dressing protects from external contamination⁵
- The PICO System promotes changes in blood flow, which may be beneficial for the wound^{*6}

Prepare Protect Progress

Smith+Nephew

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use.

Smith + Nephew Croxley Park,
Building 5, Hatters Lane,
Watford, Hertfordshire,
WD18 8YE

www.smith-nephew.com

T +44 (0) 1923 477100
F +44 (0) 1923 477101

♦Trademark of Smith+Nephew
All Trademarks acknowledged
©June 2023 Smith+Nephew
39968 | GMC1649

References:

The problem: **1.** Burns. World Health Organization. Updated March 6th, 2018. Accessed March 17th, 2023. <https://www.who.int/news-room/fact-sheets/detail/burns#:~:text=An%20estimated%20180%20000%20deaths,in%20the%20home%20and%20workplace>

Prepare, Protect, Progress: **1.** Marc G. Jeschke, et al. Nat Rev Dis Primers. 2020 Feb 13;6(1):11

VERSAJET® II Hydrosurgery System: **1.** Caputo WJ, Beggs DJ, DeFede JL, Simm L, Dharma H. A prospective randomised controlled clinical trial comparing hydrosurgery debridement with conventional surgical debridement in lower extremity ulcers. *Int Wound J.* 2008;5(2):288–294. **2.** Liu J, Ko JH, Secretov E, et al. Comparing the hydrosurgery system to conventional debridement techniques for the treatment of delayed healing wounds: a prospective, randomised clinical trial to investigate clinical efficacy and cost-effectiveness. *Int Wound J.* 2015;12(4):456–461. **3.** McAleer JP, Kaplan EM, Perisich G, Axman W. A Prospective Randomized Study Evaluating the Time Efficiency of the VERSAJET™ Hydrosurgery System and Traditional Wound Debridement. Poster presented at: ACFAS 2005; New Orleans, LA. **4.** Vanwiljck R, Kaba L, Boland S, Azero MG, Delange A, Tourbach S. Immediate skin grafting of sub-acute and chronic wounds debrided by hydrosurgery. *J Plast, Reconstr & Aesthetic Surg.* 2010;63:544–549. **5.** Allan N (2010). The impact of VERSAJET Hydrosurgical debridement on wounds containing bacterial biofilms. In Abstracts 20th Meeting of the European Tissue Repair Society 9, 77–98. **6.** Hyland EJ, D’Cruz R, Menon S, et al. Prospective, randomised controlled trial comparing Versajet hydrosurgery and conventional debridement of partial thickness paediatric burns. *Burns.* 2015;41(4):700–707. **7.** Matsumura H, Nozaki M, Watanabe K, et al. The Estimation of Tissue Loss During Tangential Hydrosurgical Debridement. *Annals Plast Surg.* 2012;69(5):521–525. **8.** Rennekampff HA, Schaller HE, Wissler D, Tanenhaus M. Debridement of Burn Wounds with a Water Jet Surgical Tool. *Burns.* 2006;32(1):64–69.

ACTICOAT® Antimicrobial Barrier Dressing: **1.** Gago M, García F, Gaztelu V, Verdú J, López P, Nolasco A. A comparison of three silver-containing dressings in the treatment of infected, chronic wounds. *Wounds.* 2008;20(10):273–278. **2.** Tredget EE, Shankowsky HA, Groenveld A, Burrell RE. A matched-pair, randomised study evaluating the efficacy and safety of ACTICOAT silver-coated dressing for the treatment of burn wounds. *J Burn Care Rehabil.* 1998;19(6):531–537. **3.** Strohal R, Schelling M, Takacs M, Jurecka W, Gruber U, Offner F. Nanocrystalline silver dressings as an efficient anti-MRSA barrier: a new solution to an increasing problem. *J Hosp Infect.* 2005;60(3):226–230. **4.** Chaloner D, Stevens J. A comparative study of two silver containing dressings, ACTICOAT 7 and Avance, in the treatment of chronic venous ulcers. Poster presented at: WUWHS2004; Paris. **5.** Wright JB, Lam K, Burrell RE. Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment. *Am J Infect Control.* 1998;26(6):572–577. **6.** Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. *Am J Infect Control.* 1999;27(4):344–350. **7.** Smith+Nephew 2008. ACTICOAT Flex 3 has antimicrobial activity in 30 minutes. Internal Report. DOF 0810018. **8.** Smith+Nephew 2008. ACTICOAT Flex 7 has antimicrobial activity in 30 minutes. Internal Report. DOF 0810014. **9.** Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of ACTICOAT Antimicrobial Barrier Dressing. *J Burn Care Rehabil.* 1999;20(3):195–200. **10.** Wright JB, Hansen D, Burrell RE. The comparative efficacy of two antimicrobial barrier dressings: *In vitro* examination of two controlled release of silver dressings. *Wounds.* 1998;10(6):179–188. **11.** Smith+Nephew 2008. Antimicrobial activity of ACTICOAT Flex 3 against a broad spectrum of wound pathogens. Internal Report. DOF 0810016. **12.** Smith+Nephew 2008. Antimicrobial activity of ACTICOAT Flex 3 dressings in a 3 day repeat challenge test. Internal Report. DOF 0810017. **13.** Smith+Nephew 2008. Antimicrobial activity of ACTICOAT Flex 7 against a broad spectrum of wound pathogens. Internal Report. DOF 0810012. **14.** Smith+Nephew 2008. Antimicrobial activity of ACTICOAT Flex 7 dressings in a 7 day repeat challenge test. Internal Report. DOF 0810013. **15.** Westaim Biomedical 2001. The antimicrobial activity of Westaim’s ACTICOAT Silver coated dressing against clinically relevant organisms over an extended period of time. Fort Saskatchewan, Alberta, Canada. Report - 971030. **16.** Smith+Nephew 2011. A prospective, open, multicentre evaluation of the use of ACTICOAT Flex dressing in the treatment of partial thickness and deep partial thickness burns. Internal Report. SR/CE/036/ACB. **17.** Smith+Nephew 2011. An evaluation of the use of ACTICOAT Flex dressings. Internal Report. SR/CIME/017.

INTRASITE® Gel and INTRASITE Conformable Hydrogel Wound Dressings: **1.** Smith+Nephew 2011. Physical and chemical properties of INTRASITE Gel APPLIPAK. Internal Report. DS/11/008/R4. **2.** Colin D, Kurring Pa, Yvon C. Managing sloughy pressure sores. *J Wound Care.* 1996;5(10):444–446. **3.** Cassino R, Ricci E, Carusone A. A conformable hydrogel in the debridement of complex necrotic wounds. Paper presented at: EWMA; 1997; Milan. **4.** Smith+Nephew 2020. Use of literature and data to support the INTRASITE Mode of Action. Internal Report. EO.AWM.PCSgen.004.v2. **5.** Flanagan M. The efficacy of a hydrogel in the treatment of wounds with non-viable tissue. **6.** Smith+Nephew 2004. Bio-activity of ACTICOAT when used with INTRASITE Gel. Internal Report. DOF 0403006. **7.** Potgieter MD, Meidany P. Evaluation of the penetration of nanocrystalline silver through various wound dressing mediums: An *in vitro* study. *Burns.* 2018;44(3):596–602. **8.** Smith+Nephew 2003. *In vitro* assessment of the compatibility of ACTICOAT and INTRASITE Gel dressings. Internal Report. DOF 0305001. **9.** Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. *Burns.* 2004;30(S1):S1–S9. **10.** Bale S, Banks V, Hagelstein S, Harding KG. A comparison of two amorphous hydrogels in the debridement of pressure sores. *Journal of Wound Care.* 1998;7(2):65–68. **11.** Young T, Williams C, Benbow M, et al. A study of two hydrogels used in the management of pressure sores. Proceedings of the Sixth European Conference on Advances in Wound Management; 1997; London. **12.** Humbert P, Faivre B, Véran Y, et al. Protease-modulating polyacrylate based hydrogel stimulates wound bed preparation in venous leg ulcers—a randomized controlled trial. *JEADV.* 2014;28(12):1742–1750.

BIOBRANE® Temporary Biosynthetic Skin Dressing: **1.** Erdman D, Hussman J, Kucan JO. Treatment of a severe alkali burn. *Burns.* 1996;22(2):141–146. **2.** Lo CH, Akbarzadeh S, McLean C, et al. Wound healing after cultured epithelial autografting in patients with massive burn injury: a cohort study. *J Plast Reconstr Aesthet Surg.* 2019;72(3):427–437. **3.** Muganza A, Cullingworth L. A Prospective Single-Centre Randomised Controlled Study to Compare the Time to Healing of Partial Thickness Burn Wounds Treated with Versajet, Biobrane and Acticoat Therapy. *Glob J Med Res.* 2014;14(6):5–12. **4.** Leshner AP, Curry RH, Evans J, et al. Effectiveness of Biobrane for treatment of partial-thickness burns in children. *J Pediatr Surg.* 2011;46(9):1759–1763. **5.** Austin RE, Merchant N, Shahrokhi S, Jeschke MG. A comparison of Biobrane and cadaveric allograft for temporizing the acute burn wound: Cost and procedural time. *Burns.* 2015;41(4):749–753. **6.** Farroha A, Frew Q, El-Muttardi N, Philp B, Dziewulski P. The Use of BIOBRANE® to Dress Split-thickness Skin Graft in Paediatric Burns. *Ann Burns Fire Disasters.* 2013;XXVI(2):94–97. **7.** Barret JP, Dziewulski P, Ramzy PI, Wolf SE, Desai MH, Herndon DN. Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns. *Plastic and Reconstructive Surgery.* 2000;105(1):62–65. **8.** Gerding RL, Imbembo AL, Frattianne RB. Biosynthetic skin substitute vs. 1% silver sulfadiazine for treatment of inpatient partial-thickness thermal burns. *J Trauma.* 1988;28(8):1265–1269. **9.** Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns (Review). Cochrane Database Syst Rev. 2008(4). **10.** Kumar RJ, Kimble RM, Boots R, Pegg SP. Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte. *ANZ J Surg.* 2004;74(8):622–626. **11.** Muganza A, Cullingworth L. A Prospective Single-Centre Randomised Controlled Study to Compare the Time to Healing of Partial Thickness Burn Wounds Treated with Versajet, Biobrane and Acticoat Therapy. *Glob J Med Res.* 2014;14(6):5–12. **12.** Cassidy C, St Peter SD, Lacey S, et al. Biobrane versus duoderm for the treatment of intermediate thickness burns in children: a prospective, randomized trial. *Burns.* 2005;31(7):890–893. **13.** Lang EM, Eiberg CA, Brandis M, Stark GB. Biobrane in the treatment of burn and scald injuries in children. *Ann Plast Surg.* 2005;55(5):485–489. **14.** Lal S, Barrow RE, Wolf SE, et al. Biobrane improves wound healing in burned children without increased risk of infection. *Shock (Augusta, Ga).* 2000;14(3):314–318; 318–319.

RENASYS® Negative Pressure Wound Therapy: **1.** Birke-Sorensen H, Malmsoj M, Rome P, et al. Evidence-based recommendations for negative pressure wound therapy: Treatment variables (pressure levels, wound filler and contact layer) - Steps towards an international consensus. *J Plast Reconstr Aesthet Surg.* 2011;64(1):S1–S16. **2.** Molnar JA, Simpson JL, Voignier DM, Morykwas MJ, Argenta LC. Management of an Acute Thermal Injury With Subatmospheric Pressure. *J Burns Wounds.* 2005;4(5):83–92. **3.** Kamolz LP, Andel H, Haslik W, Winter W, Meissl G, Frey M. Use of subatmospheric pressure therapy to prevent burn wound progression in human: first experiences. *Burns.* 2004;30(3):253–258. **4.** Dunn R, Hurd T, Chadwick P, et al. Factors associated with positive outcomes in 131 patients treated with gauze-based negative pressure wound therapy. *Int J Surg.* 2011;9(3):258–262. **5.** Chan SYC, Wong KL, Lim JXJ, Tay YLE, Nather A. The role of RENASYS-GO™ in the treatment of diabetic lower limb ulcers: a case series. *Diabet Foot Ankle.* 2014;17(5):1–7. **6.** Lima RVKS, Coltro PS, Farina Junior JA. Negative pressure therapy for the treatment of complex wounds. *Rev Col Bras Cir.* 2017;44(1):081–093. **7.** Forlee M, Zyl LV, Louw H, Nel J, Fourie N, Hartley R. A randomised controlled trial to compare the clinical efficacy and acceptability of adjustable intermittent and continuous Negative Pressure Wound Therapy (NPWT) in a new portable NPWT system. Poster presented at: European Wound Management Association (EWMA)2018; Krakow, Poland. **8.** Birke-Sorensen H, Malmsoj M, Rome P, et al. Evidence-based recommendations for negative pressure wound therapy: Treatment variables (pressure levels, wound filler and contact layer) - Steps towards an international consensus. *J Plast Reconstr Aesthet Surg.* 2011;64(1):S1–S16. **9.** Young SR, Hampton S, Martin R. Non-invasive assessment of negative pressure wound therapy using high frequency diagnostic ultrasound: oedema reduction and new tissue accumulation. *Int Wound J.* 2013;10(4):383–388. **10.** Canonico S, Campitiello F, Della Corte A, et al. Therapeutic possibilities of portable NPWT - Initial multidisciplinary observation with the negative pressure therapy device. *Acta Vulnol.* 2012;10(2):57–66.

PICO® Negative Pressure Wound Therapy: **1.** Hudson DA, Adams KG, Van Huyssteen A, Martin R, Huddleston EM. Simplified negative pressure wound therapy: clinical evaluation of an ultraportable, nocaister system. *Int Wound J.* 2015;12(2):195–201. **2.** Payne C, Edwards D. Application of the Single Use Negative Pressure Wound Therapy Device (PICO) on a Heterogeneous Group of Surgical and Traumatic Wounds. *ePlasty.* 2014;152–166. **3.** Gilchrist B, Robinson M, Jaimes H. Performance, safety, and efficacy of a single use negative pressure wound therapy system for surgically closed incision sites and skin grafts: A prospective multi-centre follow-up study. Paper presented at: SAWC; 2020; Virtual. **4.** Canonico S, Campitiello F, Della Corte A, et al. Therapeutic Possibilities of Portable NPWT Initial Multidisciplinary Observation with the Negative Pressure Therapy Device. *Acta Vulnol.* 2012;10:57–66. **5.** Smith+Nephew 2020. Bacterial barrier testing of the PICO Dressing. Internal Report. 2001002. **6.** Malmsoj M, Huddleston E, Martin R. Biological Effects of a Disposable, Canisterless Negative Pressure Wound Therapy System. *ePlasty.* 2014;14:1–15.